started · updated
Greek pharmaceutical sector sees clawback increase and Lavipharm growth
The Greek government has introduced a new ministerial decision to increase the investment clawback for pharmaceutical companies by approximately 99 million euros for the 2024-2025 period. This measure, funded through the Recovery Fund or the state budget, aims to incentivize capital expenditures in production, products, and services. The regulation allows for a potential 20% increase in funding for approved investment plans that have undergone expansion.
Separately, Lavipharm Group reported its financial results for the first half of 2026. The company saw a 24.1% increase in consolidated sales before clawback and rebate, reaching 38.5 million euros. While consolidated net profits after taxes were 2.4 million euros—a slight decrease from 2.6 million euros in the same period of 2025—this was attributed to the recognition of income from the sale of Pharma Plus in the previous year. Excluding that one-time income, net profits from continuing operations rose by 41.3%. Foreign sales grew by 35% during this period.
Entities
Greek government · Lavipharm Group · Ministry of Health · Vasilis Baloumis
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] Consolidated net profits after taxes amounted to 2.4 million euros in the first half of 2026. www.businessdaily.gr · www.iatronet.gr
- [● 2 SOURCES] Lavipharm Group's consolidated sales before clawback and rebate increased by 24.1% in the first half of 2026. www.businessdaily.gr · www.iatronet.gr
- [● 2 SOURCES] Foreign sales increased by 35% during the first half of 2026. www.businessdaily.gr · www.iatronet.gr
- [○ 1 SOURCE] The new ministerial decision allows for an increase of up to 20% for projects that have been expanded. www.sbctv.gr
- [○ 1 SOURCE] The Greek government is increasing the investment clawback for pharmaceutical companies by nearly 100 million euros for the 2024-2025 period. www.sbctv.gr